China’s Mass COVID Testing: Players And Profits Behind The Policy
New Billionaires Created
Executive Summary
Even at $2.40 per test, tens of millions of tests provided add up quickly to deplete China’s medical insurance pool. Now the government wants localities to step and pay.
You may also be interested in...
Biden Pledges A Billion COVID-19 Tests, Announces Plan Requiring Private Insurers To Pay For At-Home Diagnostics
The Biden administration announced on 13 January that it’s purchasing an additional 500 million COVID-19 tests to be distributed free to any American wanting one, bringing the total to 1 billion tests procured.
FDA Yanks Potentially Faulty COVID-19 Antibody Tests – And More May Be On The Chopping Block
After criticism it was being too lax in overseeing COVID-19 antibody tests coming to market, the US agency issued an updated guidance earlier this month tightening regulations. As a result, it has now pulled more than two dozen tests that don’t meet its standards – and more are expected to follow.
CEO Podcast: Hengrui's US Subsidiary's CEO, CMO On Chinese Pharma Going Global
While many pharma firms in China choose to partner with US companies, Jiangsu Hengrui is relying on itself to go global. The Chinese pharma giant is betting on its newly established US subsidiary Luzsana in a major move to make its wide-ranging products more available, accessible and affordable to patients in the US and the rest of the world.